- Home
- ALLK vs BCAB Comparison
ALLK vs BCAB Comparison
Compare ALLK & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- BCAB
- Stock Information
- Founded
- ALLK 2012
- BCAB 2007
- Country
- ALLK United States
- BCAB United States
- Employees
- ALLK N/A
- BCAB N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- ALLK Health Care
- BCAB Health Care
- Exchange
- ALLK Nasdaq
- BCAB Nasdaq
- Market Cap
- ALLK 23.0M
- BCAB 27.0M
- IPO Year
- ALLK 2018
- BCAB 2020
- Fundamental
- Price
- ALLK $0.33
- BCAB $0.38
- Analyst Decision
- ALLK Hold
- BCAB Buy
- Analyst Count
- ALLK 3
- BCAB 2
- Target Price
- ALLK $2.00
- BCAB $1.00
- AVG Volume (30 Days)
- ALLK 2.2M
- BCAB 525.8K
- Earning Date
- ALLK 05-08-2025
- BCAB 05-13-2025
- Dividend Yield
- ALLK N/A
- BCAB N/A
- EPS Growth
- ALLK N/A
- BCAB N/A
- EPS
- ALLK N/A
- BCAB N/A
- Revenue
- ALLK N/A
- BCAB $11,000,000.00
- Revenue This Year
- ALLK N/A
- BCAB N/A
- Revenue Next Year
- ALLK N/A
- BCAB N/A
- P/E Ratio
- ALLK N/A
- BCAB N/A
- Revenue Growth
- ALLK N/A
- BCAB N/A
- 52 Week Low
- ALLK $0.22
- BCAB $0.24
- 52 Week High
- ALLK $1.56
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- ALLK 60.40
- BCAB 60.29
- Support Level
- ALLK $0.31
- BCAB $0.30
- Resistance Level
- ALLK $0.33
- BCAB $0.34
- Average True Range (ATR)
- ALLK 0.00
- BCAB 0.04
- MACD
- ALLK 0.00
- BCAB 0.01
- Stochastic Oscillator
- ALLK 78.50
- BCAB 92.85
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.